Skip to content

Evaluations vs Other Organisms

Mat Todd edited this page Jun 10, 2021 · 11 revisions

A selection of series 4 molecules ( + the s3 singleton) were sent to the CO-ADD organization for testing of possible antibacterial and anti-yeast activity as per https://github.com/OpenSourceMalaria/OSM_To_Do_List/issues/577. Data here and raw here.

Unfortunately all tested compounds didn't show inhibition higher than ~30%. All compounds were tested at a fixed concentration of 32 ug/mL.

yeastbacteriascreen


Internal ID SMILES InChI CnChI Key
MK113-1a C12=NN=C(C3=CC=CC=C3)N1C(OCCC4=CC=CC=C4)=CN=C2 "InChI=1S/C19H16N4O/c1-3-7-15(8-4-1)11-12-24-18-14-20-13-17-21-22-19(23(17)18)16-9-5-2-6-10-16/h1-10,13-14H,11-12H2" YRTHPBSIEMFKFB-UHFFFAOYSA-N
MK126-1b COC(C=C1)=CC=C1C2=NN=C3C(OCCC4=CC=CC=C4)=NC=CN32 "InChI=1S/C20H18N4O2/c1-25-17-9-7-16(8-10-17)18-22-23-19-20(21-12-13-24(18)19)26-14-11-15-5-3-2-4-6-15/h2-10,12-13H,11,14H2,1H3" KNDAUWHMGBUKCB-UHFFFAOYSA-N
MK114-1a COC(C=C1)=CC=C1C2=NN=C3C=NC=C(OCCC4=CC=CC=C4)N32 "InChI=1S/C20H18N4O2/c1-25-17-9-7-16(8-10-17)20-23-22-18-13-21-14-19(24(18)20)26-12-11-15-5-3-2-4-6-15/h2-10,13-14H,11-12H2,1H3" FOEYJDQRLPZFOG-UHFFFAOYSA-N
MK121-1b COC(C=C1)=CC=C1C2=NN=C3C(SCCC4=CC=CC=C4)=NC=CN32 "InChI=1S/C20H18N4OS/c1-25-17-9-7-16(8-10-17)18-22-23-19-20(21-12-13-24(18)19)26-14-11-15-5-3-2-4-6-15/h2-10,12-13H,11,14H2,1H3" GEUZYLOQEWPPTC-UHFFFAOYSA-N
MK127-1a COC(C=C1)=CC=C1C2=NN=C3C=NC=C(SCCC4=CC=CC=C4)N32 "InChI=1S/C20H18N4OS/c1-25-17-9-7-16(8-10-17)20-23-22-18-13-21-14-19(24(18)20)26-12-11-15-5-3-2-4-6-15/h2-10,13-14H,11-12H2,1H3" XKLPATLXLSUHOI-UHFFFAOYSA-N
MK096-1 C12=NN=CN1C(OCCC3=CC=CC=C3)=CN=C2 "InChI=1S/C13H12N4O/c1-2-4-11(5-3-1)6-9-18-13-12-16-15-10-17(12)8-7-14-13/h1-5,7-8,10H,6,9H2" OVMOYCYDOGFLPO-UHFFFAOYSA-N
MK086-1 C12=NN=CN1C(SCCC3=CC=CC=C3)=CN=C2 "InChI=1S/C13H12N4S/c1-2-4-11(5-3-1)6-7-18-13-9-14-8-12-16-15-10-17(12)13/h1-5,8-10H,6-7H2" SFKFITTZRQEVSE-UHFFFAOYSA-N
MK105-2 C1(NCCC2=CC=CC=C2)=NC=CN3C1=NN=C3 "InChI=1S/C13H13N5/c1-2-4-11(5-3-1)6-7-14-12-13-17-16-10-18(13)9-8-15-12/h1-5,8-10H,6-7H2,(H,14,15)" ZKSCHIOOMCSXEE-UHFFFAOYSA-N
MK006-3 C12=NN=CN1C(OCCC3=CC=CC=C3)=CN=C2 "InChI=1S/C13H12N4O/c1-2-4-11(5-3-1)6-7-18-13-9-14-8-12-16-15-10-17(12)13/h1-5,8-10H,6-7H2" VFFDMAJXCFVHJC-UHFFFAOYSA-N
MK035-1 FC1=CC(CCOC2=CN=CC3=NN=C(C4=CC=C5C(NC=C5)=C4)N32)=CC=C1F "InChI=1S/C21H15F2N5O/c22-16-4-1-13(9-17(16)23)6-8-29-20-12-24-11-19-26-27-21(28(19)20)15-3-2-14-5-7-25-18(14)10-15/h1-5,7,9-12,25H,6,8H2" VHFREJHLTSVZGA-UHFFFAOYSA-N
MK065-1 FC1=CC(CCOC2=CN=CC3=NN=C(C4=CC=C(Cl)C(N)=C4)N32)=CC=C1F "InChI=1S/C19H14ClF2N5O/c20-13-3-2-12(8-16(13)23)19-26-25-17-9-24-10-18(27(17)19)28-6-5-11-1-4-14(21)15(22)7-11/h1-4,7-10H,5-6,23H2" UUAZLIWHOSTWRP-UHFFFAOYSA-N
MK067-1 FC1=CC(CCOC2=CN=CC3=NN=C(C4=CC=CC(N)=C4)N32)=CC=C1F "InChI=1S/C19H15F2N5O/c20-15-5-4-12(8-16(15)21)6-7-27-18-11-23-10-17-24-25-19(26(17)18)13-2-1-3-14(22)9-13/h1-5,8-11H,6-7,22H2" CQZOPOXKTPBXOH-UHFFFAOYSA-N
MK041-1 FC1=CC(CCOC2=CN=CC3=NN=C(C4=CC=C(N)C=C4)N32)=CC=C1F "InChI=1S/C19H15F2N5O/c20-15-6-1-12(9-16(15)21)7-8-27-18-11-23-10-17-24-25-19(26(17)18)13-2-4-14(22)5-3-13/h1-6,9-11H,7-8,22H2" PGJZGRJIPPSPJV-UHFFFAOYSA-N
MK094-1 C1(SCCC2=CC=CC=C2)=NC=CN3C1=NN=C3 "InChI=1S/C13H12N4S/c1-2-4-11(5-3-1)6-9-18-13-12-16-15-10-17(12)8-7-14-13/h1-5,7-8,10H,6,9H2" QGQSZEIXFAHGEY-UHFFFAOYSA-N
MK139-1 C1(OCCC2=CC=CC=C2)=NC=CN3C1=NN=C3C4=CC=CC=C4 "InChI=1S/C19H16N4O/c1-3-7-15(8-4-1)11-14-24-19-18-22-21-17(23(18)13-12-20-19)16-9-5-2-6-10-16/h1-10,12-13H,11,14H2" BKUOBYRSGGKOSW-UHFFFAOYSA-N
MK091-2 FC1=CC(CCOC2=CN=CC3=NN=C(C4=CC5=C(C=C4)N=CN5)N32)=CC=C1F "InChI=1S/C20H14F2N6O/c21-14-3-1-12(7-15(14)22)5-6-29-19-10-23-9-18-26-27-20(28(18)19)13-2-4-16-17(8-13)25-11-24-16/h1-4,7-11H,5-6H2,(H,24,25)" OKICKLNNAMYKHW-UHFFFAOYSA-N
MNB6-8 NC1=C2C(C=C(C3=CC(S(N)(=O)=O)=CC=C3)S2)=NC=N1 "InChI=1S/C12H10N4O2S2/c13-12-11-9(15-6-16-12)5-10(19-11)7-2-1-3-8(4-7)20(14,17)18/h1-6H,(H2,13,15,16)(H2,14,17,18)" MQMXDJVOZKMSNT-UHFFFAOYSA-N

Background

What is OSM Series 4?

Aims, Concerns and Current Interest in Series 4

Sources of Data

Structure-Activity Relationships

Modification of Core Triazolopyrazine

Modification of Pyrazine Substitution Pattern

Modification of the Triazole Substitution

Pyrazine Side Chain Modifications - Ethers

Pyrazine Side Chain Modifications - Amides

Pyrazine Side Chain Modifications - Reversed Amides

Pyrazine Side Chain Modifications - Others

Metabolites

Biological Data Currently not Incorporated into the Main Wiki Sections

Physicochemical/Metabolic Parameters

Physicochem/metabolism/PK

Metabolism ID

Aldehyde Oxidase Assay

Stages and Efficacy

Liver Stage

Gametocyte Stage

In Vivo Efficacy

Potency vs. Resistant Strains

Other Observations

Mechanism of Action, Activity and Toxicity

Mechanism of Action: Possible PfATP4 Activity Deduced from Parasite Ion Regulation Assays

hERG Activity

Toxicity

Synthetic Chemistry

Synthetic Design

Synthesis of the Ether-Linked Series

Synthesis of the Amide-Linked Series

Synthesis of the Reverse Amide- Linked Series

Synthesis of Benzylic Functionalised Ether-Linked Series

Alternative Routes to the Triazolopyrazine Core

Triazolopyrazine telesubstitution

Biofunctionalisation

Late Stage Functionalisation

Fluoroalkene Isostere

Spectroscopy

Chirality, Relevant and Desirable Compounds

Chirality/Stereogenic Centres in This Series

Other Sources of Compounds Relevant to this Series

Desirable Compounds Not Yet Synthesised

Other Evaluations

Evaluations vs Other Organisms

Strings

Strings for Google

Clone this wiki locally